Safety and Efficacy Study to Compare Smoflipid and Intralipid 20% in Pediatric Patients of 3 Months to 16 Years of Age

• Status: Recruiting
• Trial end date: 2024-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Evaluate the safety and efficacy of Smoflipid compared to standard of care lipid emulsion Intralipid 20% administered via a central vein in pediatric patients 3 months to 16 years of age who require parenteral nutrition for at least 90 days and up to 1 year.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Fresenius Kabi
• Treatments: SMOFlipid; Soybean oil, phospholipid emulsion

Criteria

Inclusion Criteria:

1. Male and female patients 3 months to 16 years of age.

2. Patients who require PN for at least 5 days/week.

3. Patients who receive 60% or more of their total energy requirements as PN at enrollment and who are expected to receive 60% or more of their total energy requirements as PN for at least 90 days.

4. Written informed consent from parent(s) or legal representative(s). If possible, patient assent must also be obtained (according to local law).

Exclusion Criteria:

1. Known hypersensitivity to fish, egg, soybean, or peanut proteins, or to any of the active ingredients or excipients of Smoflipid or Intralipid 20%.

2. Hyperlipidemia or disorders of lipid metabolism characterized by hypertriglyceridemia (serum triglyceride concentration > 250 mg/dL).

3. Inborn errors of amino acid metabolism.

4. Cardiopulmonary instability (including pulmonary edema, cardiac insufficiency, myocardial infarction, acidosis and hemodynamic instability requiring significant vasopressor support).

5. Hemophagocytic syndrome.

6. Liver enzymes (either AST, or ALT, or GGT) exceeding 5 x upper limit of normal range

7. Direct bilirubin ≥ 2.0 mg/dl

8. INR > 2.

9. Any known hepatic condition outside of Intestinal Failure-Associated Liver Disease (IFALD) that will increase direct bilirubin ≥ 2.0 mg/dl.

10. Clinically significant abnormal levels of any serum electrolyte (sodium, potassium, magnesium, calcium, chloride, phosphate).

11. Active bloodstream infection demonstrated by positive blood culture at screening.

12. Severe renal failure including patients on renal replacement therapy.

13. Abnormal blood pH, oxygen saturation, or carbon dioxide.

14. Pregnancy or lactation.

15. Participation in another clinical study.

16. Unlikely to survive longer than 90 days.